AR120458A1 - Agonista del receptor glp-1 y uso de este - Google Patents
Agonista del receptor glp-1 y uso de esteInfo
- Publication number
- AR120458A1 AR120458A1 ARP200103146A ARP200103146A AR120458A1 AR 120458 A1 AR120458 A1 AR 120458A1 AR P200103146 A ARP200103146 A AR P200103146A AR P200103146 A ARP200103146 A AR P200103146A AR 120458 A1 AR120458 A1 AR 120458A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- group
- haloalkyl
- unsubstituted
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 150000002367 halogens Chemical class 0.000 abstract 10
- 125000001188 haloalkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 230000003287 optical effect Effects 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Un compuesto representado por la fórmula química (1), un isómero óptico del compuesto, o una sal farmacéuticamente aceptable del compuesto o el isómero óptico, donde: R¹ es -C(=O)Rᵃ, donde Rᵃ es -OH u -O-(alquilo C₁₋₄); Y es -CH- o -N-; R² es uno que se selecciona del grupo que consiste en arilo C₆ a C₁₂ sustituido o insustituido, heteroarilo C₅ a C₁₂ sustituido o insustituido, heterocicloalquilo C₃ a C₈ sustituido o insustituido, alquilo C₁ a C₄ sustituido o insustituido, y cicloalquilo C₃ a C₈ sustituido o insustituido, donde el arilo, heteroarilo, heterocicloalquilo, alquilo, y cicloalquilo sustituido incluyen al menos una sustitución con -OH, -(alquilo C₁₋₄), halógeno, o -CN; Rᵇ es hidrógeno o -(alquilo C₁₋₄); J es -CH- o -N-; X es -CRᶜ- o -N-, donde Rᶜ es uno que se selecciona del grupo que consiste en -H, halógeno, -CN, -OH, -O-(alquilo C₁₋₄), -NH₂, -NO₂, y haloalquilo -C₁₋₄; W¹ es -CRᵈ-, donde Rᵈ es uno que se selecciona del grupo que consiste en -H, halógeno, -CN, -OH, -O-(alquilo C₁₋₄), -NH₂, -NO₂, y haloalquilo -C₁₋₄; W² es -CRᵉ- o -N-, donde Rᵉ es uno que se selecciona del grupo que consiste en -H, halógeno, -CN, -OH, -O-(alquilo C₁₋₄), -NH₂, -NO₂, y haloalquilo -C₁₋₄; W³ es -CRᶠ-, donde Rᶠ es uno que se selecciona del grupo que consiste en -H, halógeno, -CN, -OH, -O-(alquilo C₁₋₄), -NH₂, -NO₂, y haloalquilo -C₁₋₄; y A es un compuesto de fórmula (2), donde: Z¹ es -CRᵍ- o -N-, donde Rᵍ es uno que se selecciona del grupo que consiste en -H, halógeno, -CN, -OH, -O-(alquilo C₁₋₄), -NH₂, -NO₂, y haloalquilo -C₁₋₄; Z² es -CRʰ- o -N-, donde Rʰ es uno que se selecciona del grupo que consiste en -H, halógeno, -CN, -OH, -O-(alquilo C₁₋₄), -NH₂, -NO₂, y haloalquilo -C₁₋₄; Z³ es -CRⁱ- o -N-, donde Rⁱ es uno que se selecciona del grupo que consiste en -H, halógeno, -CN, -OH, -O-(alquilo C₁₋₄), -NH₂, -NO₂, y haloalquilo -C₁₋₄; Z⁴ es -CRʲ- o -N-, donde Rʲ es uno que se selecciona del grupo que consiste en -H, halógeno, -CN, -OH, -O-(alquilo C₁₋₄), -NH₂, -NO₂, y haloalquilo -C₁₋₄; Z⁵ es -CRᵏ- o -N-, donde Rᵏ es uno que se selecciona del grupo que consiste en -H, halógeno, -CN, -OH, -O-(alquilo C₁₋₄), -NH₂, -NO₂, y haloalquilo -C₁₋₄; y Z¹ a Z⁵ cumplen una de las siguientes condiciones i) y ii): i) al menos uno de Z¹ a Z⁵ es -N-; y ii) Z¹ es -CRᵍ-, Z² es -CRʰ-, Z³ es -CRⁱ-, Z⁴ es -CRʲ-, y Z⁵ es -CRᵏ-, y donde cuando Z¹ a Z⁵ cumplen la condición ii), el resto de fórmula (3) es un compuesto de fórmula (4) ó (5).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190146798 | 2019-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120458A1 true AR120458A1 (es) | 2022-02-16 |
Family
ID=76145757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103146A AR120458A1 (es) | 2019-11-15 | 2020-11-13 | Agonista del receptor glp-1 y uso de este |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR20210059584A (es) |
| AR (1) | AR120458A1 (es) |
| TW (2) | TW202128658A (es) |
| UY (1) | UY38958A (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220152083A (ko) | 2021-05-07 | 2022-11-15 | 주식회사 엘지화학 | 가교구조 함유 올레핀고분자 다공지지체, 이를 포함하는 리튬 이차전지용 가교구조 함유 분리막, 이의 제조 방법, 및 상기 분리막을 구비한 리튬 이차전지 |
| CA3224598A1 (en) * | 2021-08-30 | 2023-03-09 | Long Zhang | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| WO2023182869A1 (en) * | 2022-03-25 | 2023-09-28 | Ildong Pharmaceutical Co., Ltd. | Novel salt of glp-1 receptor agonist compound, preparation method thereof and pharmaceutical composition comprising thereof |
| CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008012623A1 (en) * | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| JP6637641B1 (ja) * | 2016-12-16 | 2020-01-29 | ファイザー・インク | Ｇｌｐ−１受容体アゴニストおよびその使用 |
| KR20220092909A (ko) * | 2019-10-25 | 2022-07-04 | 길리애드 사이언시즈, 인코포레이티드 | Glp-1r 조절 화합물 |
-
2020
- 2020-02-24 KR KR1020200022485A patent/KR20210059584A/ko unknown
- 2020-11-13 AR ARP200103146A patent/AR120458A1/es unknown
- 2020-11-13 TW TW109139808A patent/TW202128658A/zh unknown
- 2020-11-13 TW TW109139809A patent/TWI786467B/zh active
- 2020-11-13 UY UY0001038958A patent/UY38958A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210059584A (ko) | 2021-05-25 |
| TWI786467B (zh) | 2022-12-11 |
| UY38958A (es) | 2021-05-31 |
| TW202128658A (zh) | 2021-08-01 |
| TW202128659A (zh) | 2021-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120458A1 (es) | Agonista del receptor glp-1 y uso de este | |
| AR112774A1 (es) | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona | |
| ES2559672T3 (es) | Derivados halogenados de benzamida | |
| ES2585330T3 (es) | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto inhibitorio en la producción de quinurenina | |
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| ATE406365T1 (de) | Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren | |
| AR118724A1 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| AR112338A2 (es) | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno | |
| AR058719A1 (es) | Derivados de isoxazol-4-il-oxadiazol | |
| AR117398A1 (es) | Inhibidores de la señalización mediada por tirosina cinasa 2 | |
| CA2890886A1 (en) | Indole carboxamide derivatives as p2x7 receptor antagonists | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| EA202092923A1 (ru) | Полициклическое производное пиридона | |
| MX2011013294A (es) | Antagonistas de la trayectoria de hedgehog y aplicaciones terapeuticas de los mismos. | |
| PE20190980A1 (es) | Compuestos terapeuticos y metodos para utilizarlos | |
| CO5700777A2 (es) | Derivados de 4-(2-fenilsulfanil-fenil)-1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de serotonina | |
| ES2571741T3 (es) | Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa | |
| AR121744A1 (es) | MODULADORES DE a 1-ANTITRIPSINA | |
| AR117539A1 (es) | INHIBIDORES DE TGF-bR1 (ALK5) ÚTILES PARA TRATAR TRASTORNOS DE PROLIFERACIÓN CELULAR | |
| BRPI0408160B1 (pt) | Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo | |
| KR20150081132A (ko) | 신규한 인돌 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| Sarbu et al. | Synthesis of Iodine Containing Mesoionic 2-(1, 3-Dithiolium) phenolates | |
| AR118557A1 (es) | Quelantes de hierro derivados del ácido 4-(2,4-bis(2-hidroxifenil)-1h-imidazol-1-il)benzoico | |
| CO6220909A2 (es) | Moduladores de cannabinoides hexahidro-cicloheptapirazol | |
| AR092821A1 (es) | Conjugado de derivado de acido graso-polimero |